Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations

Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations

Introduction: The efficacy of targeted therapies in oncogene-driven lung adenocarcinomas (LUADs) has been well established; however, the benefit for EGFR-mutant or ALK-rearranged lung squamous cell carcinomas (LUSCs) is less known, partially owing to the rarity of the incidence. Methods: We reviewed...

Full description

Bibliographic Details
Main Authors: Whitney E. Lewis, PharmD, Lingzhi Hong, MD, PhD, Frank E. Mott, MD, George Simon, MD, Carol C. Wu, MD, Waree Rinsurongkawong, MS, MS, PhD, J. Jack Lee, MS, PhD, Vincent K. Lam, MD, John V. Heymach, MD, PhD, Jianjun Zhang, MD, PhD, Xiuning Le, MD, PhD
Format: Article
Language:English
Published: Elsevier 2021-11-01
Series:JTO Clinical and Research Reports
Subjects:
Lung squamous cell carcinoma
Targeted therapy
Tyrosine kinase inhibitor
EGFR
ALK
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364321000965

Internet

http://www.sciencedirect.com/science/article/pii/S2666364321000965

Similar Items